IMU 0.00% 5.2¢ imugene limited

Media Thread, page-14456

  1. 219 Posts.
    lightbulb Created with Sketch. 396
    I would like to thank Bose for putting the government website link for the Azer-Cel.
    I just cut and pasted the details from that site on here.
    A very good pick up by Udaboy1 in that the Azercel trial was originally referred to as a 1b trial .
    The clarity required from IMU is around the date extension is essential(bleeding obvious I know).
    Whilst my guts are turning about what the news might be, the trial has NOT been stopped. Its being used in trial and I agree the representations by IMU to date even as late as last month have been that trial results are according to expectation and are very very promising.
    Registrational Trial has always been the aim on Purchase of technology and was why it was purchased as a quick way to get a proven drug that is complimentary to IMU technology to market.

    So lets hope we hear a clarification. In my view they must clarify this point.
    I do feel for us long term holders trying to read the tea leaves.
    I have felt the communication by IMU has improved despite what I am saying above with known times expected for data read outs.

    I live in hope for a great announcement about great data for either Azercel or Oncarlytics.
    I am still a believer in their world class technology.
    I am still a believer to back self interest and the management have plenty of skin in the game and they are not leaving and have provided themselves more shares in past 12 months .They believe in it.

    Good luck to all Long term Holders
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
5.2¢
Change
0.000(0.00%)
Mkt cap ! $382.1M
Open High Low Value Volume
5.2¢ 5.3¢ 5.1¢ $525.2K 10.13M

Buyers (Bids)

No. Vol. Price($)
3 92800 5.2¢
 

Sellers (Offers)

Price($) Vol. No.
5.3¢ 1045565 9
View Market Depth
Last trade - 16.10pm 23/08/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.